Wei Binxian 4

What Happened

• Wei Binxian, a director of Palisade Bio, was granted 592,300 restricted stock units (RSUs) on June 10, 2026. On the same date, 20,200 RSUs vested/converted into common shares, and 20,200 shares were disposed at $0 (reported as a derivative disposition).
• The grant is an award (no cash purchase). The conversion/derivative entries show no cash proceeds reported; the $0 disposal typically reflects shares withheld to satisfy tax withholding rather than an open-market sale.

Key Details

• Transaction date(s): June 10, 2026 (reported on Form 4 filed June 12, 2026; Accession 0001493152-26-028574).
• Entries reported:
  • Award/Grant (A): 592,300 RSUs granted (no price reported).
  • Exercise/Conversion (M): 20,200 shares acquired (no price reported).
  • Exercise/Conversion (M): 20,200 shares disposed at $0 (derivative).
• Shares owned after the transaction: not specified in the provided filing details.
• Footnotes:
  • F1: The 592,300 RSU grant vests in three equal annual installments; first installment vests at the earlier of the 2027 annual meeting or June 10, 2027, subject to continued service.
  • F2: The 20,200 RSUs referenced vested on June 10, 2026.
  • F3: Describes vesting schedule for another RSU grant (three equal annual installments beginning earlier dates).
• Filing timeliness: Form 4 filed two days after the transactions (no late filing flag indicated).

Context

• RSU grants and vesting are compensation events, not open-market purchases or sales; they do not necessarily indicate the insider is buying or selling based on market views.
• The $0 disposal on conversion is commonly how companies report shares withheld to cover tax obligations when RSUs vest (i.e., not a cash sale to a third party).
• Retail investors often view purchases as more informative than grants, but grant size can be relevant for assessing potential future dilution or management incentives.